Genscript Biotech 将来の成長

Future 基準チェック /56

Genscript Biotech利益と収益がそれぞれ年間112.7%と39.9%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に9.5% 112.5%なると予測されています。

主要情報

112.7%

収益成長率

112.5%

EPS成長率

Life Sciences 収益成長	44.8%
収益成長率	39.9%
将来の株主資本利益率	9.5%
アナリストカバレッジ	Good
最終更新日	23 Oct 2024

今後の成長に関する最新情報

Analysts Have Been Trimming Their Genscript Biotech Corporation (HKG:1548) Price Target After Its Latest Report

Apr 03

Recent updates

Market Still Lacking Some Conviction On Genscript Biotech Corporation (HKG:1548)

Nov 19

Is Genscript Biotech (HKG:1548) Using Debt In A Risky Way?

Oct 01

What Is Genscript Biotech Corporation's (HKG:1548) Share Price Doing?

Sep 16

After Leaping 44% Genscript Biotech Corporation (HKG:1548) Shares Are Not Flying Under The Radar

Aug 02

Slammed 28% Genscript Biotech Corporation (HKG:1548) Screens Well Here But There Might Be A Catch

Jun 05

A Look At The Fair Value Of Genscript Biotech Corporation (HKG:1548)

May 10

Is Genscript Biotech (HKG:1548) A Risky Investment?

Apr 13

Investors Appear Satisfied With Genscript Biotech Corporation's (HKG:1548) Prospects As Shares Rocket 29%

Mar 13

Genscript Biotech Corporation (HKG:1548) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Jan 26

Is Genscript Biotech (HKG:1548) A Risky Investment?

Nov 21

Is Genscript Biotech (HKG:1548) A Risky Investment?

Aug 22

Time To Worry? Analysts Just Downgraded Their Genscript Biotech Corporation (HKG:1548) Outlook

Apr 04

Analysts Have Been Trimming Their Genscript Biotech Corporation (HKG:1548) Price Target After Its Latest Report

Apr 03

Is Genscript Biotech (HKG:1548) A Risky Investment?

Apr 02

Genscript Biotech Corporation (HKG:1548) Shares Could Be 25% Below Their Intrinsic Value Estimate

Feb 07

What Is Genscript Biotech Corporation's (HKG:1548) Share Price Doing?

Dec 14

Genscript Biotech Corporation (HKG:1548) Shares Could Be 22% Below Their Intrinsic Value Estimate

Nov 09

Could The Genscript Biotech Corporation (HKG:1548) Ownership Structure Tell Us Something Useful?

Mar 20

Are Insiders Selling Genscript Biotech Corporation (HKG:1548) Stock?

Feb 13

Did The Underlying Business Drive Genscript Biotech's (HKG:1548) Lovely 753% Share Price Gain?

Jan 09

業績と収益の成長予測

SEHK:1548 - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	2,680	255	-49	778	11
12/31/2025	1,809	42	-200	97	12
12/31/2024	1,200	-170	-330	-99	12
6/30/2024	1,010	-177	-276	-20	N/A
3/31/2024	925	-136	-410	-153	N/A
12/31/2023	840	-95	-543	-287	N/A
9/30/2023	773	-140	-506	-266	N/A
6/30/2023	707	-185	-523	-245	N/A
3/31/2023	667	-206	-431	-183	N/A
12/31/2022	626	-227	-339	-120	N/A
9/30/2022	598	-315	-321	-142	N/A
6/30/2022	570	-403	-304	-163	N/A
3/31/2022	530	-381	-289	-150	N/A
12/31/2021	490	-359	-274	-137	N/A
9/30/2021	483	-265	-265	-127	N/A
6/30/2021	454	-183	-256	-118	N/A
3/31/2021	422	-194	-268	-134	N/A
12/31/2020	391	-205	-279	-151	N/A
9/30/2020	354	-194	-171	-48	N/A
6/30/2020	318	-183	-64	54	N/A
3/31/2020	296	-140	-103	12	N/A
12/31/2019	273	-97	-142	-30	N/A
9/30/2019	257	-59	-207	-116	N/A
6/30/2019	241	-22	-272	-202	N/A
3/31/2019	236	0	-18	53	N/A
12/31/2018	231	21	236	308	N/A
9/30/2018	216	24	266	338	N/A
6/30/2018	201	27	297	369	N/A
3/31/2018	177	26	N/A	195	N/A
12/31/2017	153	26	N/A	21	N/A
9/30/2017	139	27	N/A	24	N/A
6/30/2017	125	28	N/A	27	N/A
3/31/2017	120	27	N/A	30	N/A
12/31/2016	115	26	N/A	33	N/A
9/30/2016	107	26	N/A	29	N/A
6/30/2016	99	25	N/A	25	N/A
3/31/2016	93	21	N/A	22	N/A
12/31/2015	87	18	N/A	20	N/A
9/30/2015	82	13	N/A	18	N/A
6/30/2015	78	8	N/A	16	N/A
3/31/2015	74	7	N/A	14	N/A
12/31/2014	70	6	N/A	12	N/A
12/31/2013	60	6	N/A	12	N/A

アナリストによる今後の成長予測

収入対貯蓄率: 1548は今後 3 年間で収益性が向上すると予測されており、これは貯蓄率 ( 2.3% ) よりも高い成長率であると考えられます。

収益対市場: 1548今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。

高成長収益: 1548今後 3 年以内に収益を上げることが予想されます。

収益対市場: 1548の収益 ( 39.9% ) Hong Kong市場 ( 7.8% ) よりも速いペースで成長すると予測されています。

高い収益成長: 1548の収益 ( 39.9% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: 1548の自己資本利益率は、3年後には低くなると予測されています ( 9.5 %)。

Genscript Biotech 将来の成長

Future 基準チェック /56

主要情報

今後の成長に関する最新情報

Consensus EPS estimates fall by 46%

Consensus estimates of losses per share improve by 12%

Consensus EPS estimates upgraded to US$0.054 loss, revenue downgraded

Consensus revenue estimates fall by 19%

Analysts Have Been Trimming Their Genscript Biotech Corporation (HKG:1548) Price Target After Its Latest Report

Consensus forecasts updated

Recent updates

Market Still Lacking Some Conviction On Genscript Biotech Corporation (HKG:1548)

Genscript Biotech Corporation Appoints Aylin Kosova Bilgin Has Joined as the First-Ever Chief Marketing Officer for GenScript Life Science Group

Board Member recently sold HK$901k worth of stock

Now 22% overvalued after recent price rise

Is Genscript Biotech (HKG:1548) Using Debt In A Risky Way?

Genscript Biotech Corporation Announces Late-Breaking Long-Term Overall Survival Data from Cartitude-4 Study in Multiple Myeloma

What Is Genscript Biotech Corporation's (HKG:1548) Share Price Doing?

Genscript Biotech Corporation Announces Board Appointments

Consensus EPS estimates fall by 46%

First half 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

After Leaping 44% Genscript Biotech Corporation (HKG:1548) Shares Are Not Flying Under The Radar

Genscript Biotech Corporation to Report First Half, 2024 Results on Aug 09, 2024

Genscript Biotech Corporation Announces Board Resignations and Changes in Composition of Board Committees

GenScript Biotech Corporation Launches FLASH Gene Service: The Most Affordable Gene Synthesis Solution on the Market

Slammed 28% Genscript Biotech Corporation (HKG:1548) Screens Well Here But There Might Be A Catch

Now 22% undervalued after recent price drop

GenScript Biotech Corporation Announces Self-Amplifying RNA Synthesis Service for Advanced Therapeutic Applications

A Look At The Fair Value Of Genscript Biotech Corporation (HKG:1548)

Full year 2023 earnings: EPS exceeds analyst expectations

Now 25% undervalued after recent price drop

Insider recently sold HK$1.0m worth of stock

Is Genscript Biotech (HKG:1548) A Risky Investment?

Genscript Biotech Corporation Announces Directorate Appointments and Change in Composition of Board Committee

Board Member recently sold HK$455k worth of stock

Consensus estimates of losses per share improve by 12%

Consensus EPS estimates upgraded to US$0.054 loss, revenue downgraded

Investors Appear Satisfied With Genscript Biotech Corporation's (HKG:1548) Prospects As Shares Rocket 29%

Genscript Biotech Corporation, Annual General Meeting, May 17, 2024

Full year 2023 earnings: EPS exceeds analyst expectations

Genscript Announces Appointment of Dr. David R. Liu to the Scientific Advisory Board

New minor risk - Profitability

Genscript Biotech Corporation to Report Fiscal Year 2023 Final Results on Mar 09, 2024

Genscript Biotech Corporation (HKG:1548) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Executive Chairman recently sold HK$610k worth of stock

Executive Chairman exercised options and sold HK$4.5m worth of stock

Is Genscript Biotech (HKG:1548) A Risky Investment?

Independent Non-Executive Director exercised options and sold HK$1.6m worth of stock

Non-Executive Director exercised options and sold HK$2.4m worth of stock

GenScript Biotech Corporation Expands its IVT mRNA Synthesis Portfolio with Addition of Customized Circular RNA and Lipid Nanoparticles Formulation Services

Is Genscript Biotech (HKG:1548) A Risky Investment?

First half 2023 earnings released: US$0.044 loss per share (vs US$0.063 loss in 1H 2022)

Genscript Biotech Corporation to Report First Half, 2023 Results on Aug 19, 2023

Insider recently sold HK$1.4m worth of stock

Consensus revenue estimates fall by 19%

Time To Worry? Analysts Just Downgraded Their Genscript Biotech Corporation (HKG:1548) Outlook

Analysts Have Been Trimming Their Genscript Biotech Corporation (HKG:1548) Price Target After Its Latest Report

Is Genscript Biotech (HKG:1548) A Risky Investment?

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Genscript Biotech Corporation (HKG:1548) Shares Could Be 25% Below Their Intrinsic Value Estimate

Now 24% undervalued

Now 20% undervalued

Genscript Biotech Corporation Announces Chief Executive Officer Changes

Genscript Biotech Corporation Announces Redesignation of Dr. Zhang Fangliang from A Non-Executive Director to an Executive Director with Effect from December 17, 2022

What Is Genscript Biotech Corporation's (HKG:1548) Share Price Doing?

Less than half of directors are independent

Genscript Biotech Corporation (HKG:1548) Shares Could Be 22% Below Their Intrinsic Value Estimate

Is Genscript Biotech (HKG:1548) Using Debt Sensibly?

Consensus forecasts updated

First half 2022 earnings released: US$0.063 loss per share (vs US$0.046 loss in 1H 2021)

Genscript Biotech Corporation to Report First Half, 2022 Results on Aug 31, 2022

Genscript Biotech Corporation Provides Earnings Guidance for the Six Months Ended June 30, 2022

Genscript Biotech Corporation Announces Board Changes

Co-Founder exercised options and sold HK$327k worth of stock

Genscript Biotech Corporation Announces Board Changes

Less than half of directors are independent

Health Check: How Prudently Does Genscript Biotech (HKG:1548) Use Debt?

Genscript Biotech Corporation, Annual General Meeting, May 27, 2022

Genscript Biotech Corporation Provides Earnings Guidance for the Year Ended 31 December 2021

Consensus forecasts updated